These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9114726)

  • 1. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.
    Curzon G; Gibson EL; Oluyomi AO
    Trends Pharmacol Sci; 1997 Jan; 18(1):21-5. PubMed ID: 9114726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine.
    Caccia S; Confalonieri S; Bergami A; Fracasso C; Anelli M; Garattini S
    Pharmacol Biochem Behav; 1997 Aug; 57(4):851-6. PubMed ID: 9259015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux.
    Johnson GJ; Leis LA; Dunlop PC; Weir EK
    J Thromb Haemost; 2003 Dec; 1(12):2663-8. PubMed ID: 14675103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors.
    Vickers SP; Dourish CT; Kennett GA
    Neuropharmacology; 2001 Aug; 41(2):200-9. PubMed ID: 11489456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
    Wellman PJ; Jones SL; Miller DK
    Pharmacol Biochem Behav; 2003 Apr; 75(1):103-14. PubMed ID: 12759118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline.
    Garattini S; Bizzi A; Caccia S; Mennini T
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S43-50. PubMed ID: 1338321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release.
    Oluyomi AO; Gibson EL; Barnfield AM; Curzon G
    Eur J Pharmacol; 1994 Oct; 264(1):111-5. PubMed ID: 7828639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine.
    Welch JT; Lim DS
    Bioorg Med Chem; 2007 Nov; 15(21):6659-66. PubMed ID: 17765553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions.
    Javed A; Van De Kar LD; Gray TS
    Brain Res; 1997 Nov; 774(1-2):94-105. PubMed ID: 9452197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2C receptor modulation and the treatment of obesity.
    Bickerdike MJ; Vickers SP; Dourish CT
    Diabetes Obes Metab; 1999 Jul; 1(4):207-14. PubMed ID: 11228755
    [No Abstract]   [Full Text] [Related]  

  • 11. Parabrachial infusion of D-fenfluramine reduces food intake. Blockade by the 5-HT(1B) antagonist SB-216641.
    Simansky KJ; Nicklous DM
    Pharmacol Biochem Behav; 2002 Apr; 71(4):681-90. PubMed ID: 11888559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine.
    Glatz AC; Ehrlich M; Bae RS; Clarke MJ; Quinlan PA; Brown EC; Rada P; Hoebel BG
    Pharmacol Biochem Behav; 2002; 71(1-2):197-204. PubMed ID: 11812523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological actions of drugs affecting serotonin and eating.
    Garattini S
    Obes Res; 1995 Nov; 3 Suppl 4():463S-470S. PubMed ID: 8697044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats.
    Lightowler S; Wood M; Brown T; Glen A; Blackburn T; Tulloch I; Kennett G
    Eur J Pharmacol; 1996 Jan; 296(2):137-43. PubMed ID: 8838449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects.
    Rothman RB; Baumann MH
    Pharmacol Biochem Behav; 2002 Apr; 71(4):825-36. PubMed ID: 11888573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus.
    McMahon LR; Wellman PJ
    Physiol Behav; 1996 Jan; 59(1):63-9. PubMed ID: 8848492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection.
    Curzon G; Gibson EL
    Adv Exp Med Biol; 1999; 467():95-100. PubMed ID: 10721044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation of the anorectic actions of 5-HTP and fenfluramine.
    Fletcher PJ; Burton MJ
    Psychopharmacology (Berl); 1986; 89(2):216-20. PubMed ID: 3088639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the pharmacology of serotoninergic appetite-suppressive drugs.
    Garattini S
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S41-8. PubMed ID: 1338385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milnacipran, a serotonin and norepinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice.
    Nonogaki K; Nozue K; Kuboki T; Oka Y
    Am J Physiol Regul Integr Comp Physiol; 2007 May; 292(5):R1775-81. PubMed ID: 17218444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.